Original Study|Articles in Press

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting

Published:March 18, 2023DOI:


      • This real-world study evaluated biomarker testing and targeted therapy in mNSCLC.
      • At least 1 biomarker test was received by 89.4% of patients with mNSCLC.
      • Targeted therapy was used in 62.4% of patients with a positive biomarker test.
      • Increases in biomarker testing were observed after national guideline updates.
      • Despite recent improvements, there remain gaps in biomarker testing and treatment.



      This study was designed to describe real-world changes in biomarker testing among patients with non-squamous, metastatic non-small cell lung cancer (mNSCLC) in a community oncology setting from 2015 to 2020.

      Patients and Methods

      This retrospective study randomly selected 500 adult patients diagnosed with nonsquamous mNSCLC to undergo chart review and data extraction. Data were extracted and validated by 2 independent abstractors. Biomarker testing rates were described before and after national guideline updates and FDA approval of targeted agents.


      At least 1 biomarker test was received by 89.4% of patients with mNSCLC. Of all patients, 46.6%, 34.6%, and 8.2% received both single-gene and next generation sequencing (NGS)-based testing, single-gene testing only, and NGS-based testing only, respectively. However, there were changes in testing rates at the time of drug approvals for targeted agents. Biomarker testing increased for ALK (45.0% before to 78.3% after ALK-targeted drug approval), BRAF (from 20.0% to 67.8%), EGFR (from 20.0% to 78.2%), NTRK (from 34.6% to 55.7%), and ROS1 (increased from 29.6% before approval to 74.2% after). Biomarker testing increased after changes were made to national guidelines for BRAF (from 18.8% before to 68.1% after inclusion in guidelines), NTRK (from 37.2% to 56.5%), and ROS1 (increased from 40.8% to 74.5% after guideline updates). Targeted therapy was received by 62.4% of patients with a positive biomarker.


      Increases in biomarker testing rates were observed relative to targeted agent approvals and national guideline updates. However, many patients with non-squamous mNSCLC did not receive full genotyping in accordance with national guidelines and represent an opportunity to identify reasons and solutions for barriers to care.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A
        Cancer Statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
      1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. 2019.

        • Travis WD
        • Brambilla E
        • Nicholson AG
        • et al.
        The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.
        J Thorac Oncol. 2015; 10: 1243-1260
        • Barlesi F
        • Mazieres J
        • Merlio J-P
        • et al.
        Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
        Lancet North Am Ed. 2016; 387: 1415-1426
        • Kris MG
        • Johnson BE
        • Berry LD
        • et al.
        Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
        JAMA. 2014; 311: 1998-2006
        • Abrahams E.
        Right drug—right patient—right time: Personalized Medicine Coalition.
        Clin Translat Sci. 2008; 1: 11-12
        • Mehta A
        • Vasudevan S
        • Sharma SK
        • et al.
        Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape.
        Applied Cancer Res. 2020; 40: 1-12
        • Yu TM
        • Morrison C
        • Gold EJ
        • Tradonsky A
        • Layton AJ.
        Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of oncomine dx target test for advanced non–small-cell lung cancer: a single-center analysis.
        Clin Lung Cancer. 2019; 20: 20-29
        • Vanderwalde AM
        • Ma E
        • Yu E
        • et al.
        NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).
        J Clin Oncol. 2021; 39: 288
        • Robert NJ
        • Nwokeji ED
        • Espirito JL
        • et al.
        Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
        J Clin Oncol. 2021; 39: 9004
        • Nadler E
        • Pavilack M
        • Clark J
        • Espirito J
        • Fernandes A.
        Biomarker testing rates in patients with advanced non-small cell lung cancer treated in the community.
        J Cancer Ther. 2019; 10: 971-984
        • John A
        • Yang B
        • Shah R
        Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using real-world electronic health record data.
        Adv Ther. 2021; 38: 1552-1566
        • Pennell NA
        • Mutebi A
        • Zhou Z-Y
        • et al.
        Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model.
        JCO Prec Oncol. 2019; : 1-9
        • Kris MG
        • Johnson BE
        • Berry LD
        • et al.
        Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
        JAMA. 2014; 311: 1998-2006
        • Pennell NA
        • Zhou J
        • Hobbs B.
        A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States.
        J Clin Oncol. 2020; 38: 9529
        • Ettinger DS
        • Wood DE
        • Aisner DL.
        NCCN Guidelines insights: non–small cell lung lancer, Version 2.2021.
        J NatL Compr Cancer Net. 2021; 19: 254-266
        • Lindeman NI
        • Cagle PT
        • Aisner DL
        • et al.
        Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology.
        J Thorac Oncol. 2018; 13: 323-358
        • Kalemkerian GP
        • Narula N
        • Kennedy EB
        • et al.
        Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update.
        J Clin Oncol. 2018; 36: 911-919
        • Bruno DS
        • Hess LM
        • Li X
        • Zhu YE
        • Patel M
        Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States.
        JCO Precision Oncology. 2022; 6: 1-16
      2. US FDA. Oncology (Cancer) /Hematologic malignancies approval notifications. Available at:, accessed 2021.

        • Bernicker EH
        • Xiao Y
        • Abraham A
        • et al.
        Adherence to national comprehensive cancer network ALK testing guidelines for patients with advanced non-small cell lung cancer in U.S. community medical centers.
        Oncologist. 2021; 26e1050-e1057
        • Bristow RE
        • Chang J
        • Ziogas A
        • Anton-Culver H
        Adherence to treatment guidelines for ovarian cancer as a measure of quality care.
        Obstet Gynecol. 2013; 121: 1226-1234
        • Kumar P
        • Rosario MD
        • Chang J
        • et al.
        Population-based analysis of National Comprehensive Cancer Network (NCCN) guideline adherence for patients with anal squamous cell carcinoma in California.
        J Clin Oncol. 2021; 39: 1
        • Molena D
        • Mungo B
        • Stem M
        • Poupore AK
        • Chen SY
        • Lidor AO
        Does quality of care matter? A study of adherence to national comprehensive cancer network guidelines for patients with locally advanced esophageal cancer.
        J Gastrointest Surg. 2015; 19: 1739-1747
        • Boehmer L
        • Roy U
        • Schrag J
        • et al.
        Perceptions of biomarker testing for underserved patients with lung cancer: a mixed-methods survey of US-based oncology clinicians. International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung.
        Cancer. 2021; 16: S863-864